Diabetes and Atherosclerosis: Old Players in a New Field, Osteoporosis

Curr Vasc Pharmacol. 2018;16(6):524-527. doi: 10.2174/1570161116666171205104851.

Authors

Stavroula A Paschou¹, Panagiotis Anagnostis², Andromachi Vryonidou³, Dimitrios G Goulis²

Affiliations

¹ Division of Endocrinology and Diabetes, "Aghia Sophia" Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
² Unit of Reproductive Endocrinology, First Department of Obstetrics and Gynaecology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
³ Department of Endocrinology and Diabetes, Hellenic Red Cross Hospital, Athens, Greece.

PMID: 29210657
DOI: 10.2174/1570161116666171205104851

No abstract available

Publication types

Editorial

MeSH terms

Atherosclerosis / blood
Atherosclerosis / diagnosis
Atherosclerosis / drug therapy
Atherosclerosis / epidemiology*
Biomarkers / blood
Bone Density
Bone Density Conservation Agents / therapeutic use
Bone Remodeling* / drug effects
Diabetes Mellitus, Type 1 / blood
Diabetes Mellitus, Type 1 / drug therapy
Diabetes Mellitus, Type 1 / epidemiology*
Diabetes Mellitus, Type 2 / blood
Diabetes Mellitus, Type 2 / drug therapy
Diabetes Mellitus, Type 2 / epidemiology*
Humans
Hypoglycemic Agents / therapeutic use
Osteoporosis / blood
Osteoporosis / drug therapy
Osteoporosis / epidemiology*
Osteoporosis / physiopathology
Prognosis
Risk Assessment
Risk Factors
Risk Reduction Behavior

Substances

Biomarkers
Bone Density Conservation Agents
Hypoglycemic Agents